Notice to Readers: Information contained in our press releases should be considered accurate only as of the date of the release. Information in any press release may be superseded by more recent information we have disclosed in later press releases, filings with the Securities and Exchange Commission (“SEC”) or otherwise. Press releases may contain forward-looking statements based on the expectations of our management as of the date of the release. Actual results may materially differ based on several factors, including those described in the press releases and filings with the SEC.
2003 |2002 |2001 | 2000 | Back to main index |
12/19/2002
BIOGEN APPOINTS BOB HAMM SENIOR VICE PRESIDENT OF NORTH AMERICAN COMMERCIAL OPERATIONS
12/17/2002
12/16/2002
BIOGEN NAMES WHAIJEN SOO, M.D., Ph.D. AS SENIOR VICE PRESIDENT, MEDICAL RESEARCH
11/26/2002
11/22/2002
EARLY RESULTS SUGGEST ALEFACEPT PLUS LIGHT THERAPY MAY CLEAR PSORIASIS
11/14/2002
10/18/2002
Biogen and Schering-Plough Settle Royalty Payment Arbitration
10/18/2002
BIOGEN ANNOUNCES THIRD QUARTER 2002 EARNINGS
09/12/2002
Biogen’s AMEVIVE® (alefacept) Application On Track for Early 2003 Approval
08/26/2002
Biogen Statement on The Wall Street Journal Generic Drug Story
08/22/2002
BIOGEN OPENS COMMUNITY LABORATORY, STATE-OF-THE-ART TEACHING FACILITY
07/30/2002
BIOGEN ANNOUNCES RESULTS FROM CDP 571 STUDIES IN CROHN’S DISEASE
07/29/2002
BIOGEN SCIENTISTS PART OF TEAM THAT ADVANCES UNDERSTANDING OF ANGIOGENESIS AND INFLAMMATION
07/25/2002
BIOGEN UNVEILS ENHANCED MULTIPLE SCLEROSIS WEB SITE
07/18/2002
BIOGEN ANNOUNCES SECOND QUARTER 2002 EARNINGS PER SHARE OF $0.29
07/16/2002
JIM VINCENT RETIRES AND JIM MULLEN ELECTED CHAIRMAN OF THE BOARD OF DIRECTORS OF BIOGEN
07/09/2002
BIOGEN NAMES CHRISTINE CARBERRY AS VICE PRESIDENT, PROGRAM AND ALLIANCE MANAGEMENT
06/13/2002
BIOGEN RECEIVES “COMPLETE RESPONSE” LETTER FROM FDA ON AMEVIVE® (alefacept) APPLICATION
06/07/2002
BIOGEN ANNOUNCES REVISED 2002 FINANCIAL GUIDANCE
05/23/2002
FDA Advisory Committee Recommends Approval of Biogen’s AMEVIVE®
05/21/2002
05/20/2002
BIOGEN ANNOUNCES $25,000 ANNUAL COMMITMENT TO CROWN PRINCE FREDERIK FUND
05/20/2002
05/16/2002
AVONEX® (Interferon beta-1a) GAINS MEDICARE COVERAGE
05/10/2002
BIOGEN NAMES MICHAEL KOWOLENKO, PH.D. AS VICE PRESIDENT, GLOBAL QUALITY
05/08/2002
BIOGEN DEDICATES TWO NEW WORLD-CLASS FACILITIES IN RESEARCH TRIANGLE PARK, NORTH CAROLINA
05/06/2002
BIOGEN REVAMPS MULTIPLE SCLEROSIS WEB SITE
05/01/2002
BIOGEN LAUNCHES PSORIASISSUPPORT.COM
04/24/2002
04/24/2002
BIOGEN ANNOUNCES FIRST QUARTER 2002 EARNINGS PER SHARE OF $0.47
04/18/2002
New Long-Term Data on AVONEX® (Interferon beta-1a)
04/16/2002
04/08/2002
BIOGEN NAMED PROJECT EXCELLENCE AWARD WINNER
04/02/2002
BIOGEN NAMES JOHN PALMER AS SENIOR VICE PRESIDENT, CORPORATE DEVELOPMENT
04/01/2002
03/26/2002
BIOGEN AND MIT ESTABLISH TOXICOLOGY FELLOWSHIP PROGRAM
03/25/2002
ECKHARD PFEIFFER ELECTED TO BIOGEN BOARD OF DIRECTORS
03/12/2002
FDA SAYS NO CLINICAL SUPERIORITY IN LABELING FOR REBIF®
03/08/2002
BIOGEN’S AVONEX® READY TO COMPETE AGAINST THIRD INTERFERON
02/22/2002
Biogen to Present at the Lehman Brothers’ Global Health Care Conference
01/24/2002
BIOGEN SETTLES PATENT LITIGATION WITH BERLEX LABORATORIES
01/24/2002
BIOGEN DELIVERS ON OPERATING EARNINGS GUIDANCE OF $1.90 PER SHARE AFTER ONE-TIME CHARGES
2003 |2002 | 2001 | 2000 | Back to main index |